GRR! Rebrands to Heidelberg Materials Giant Resource Recovery (GRR!) will rebrand to Heidelberg Materials Giant Resource Recovery (GRR) effective immediately. GlobeNewswire June 02, 2025 Irving, Texas, June 02, 2025 (GLOBE NEWSWIRE) — Heidelberg Materials North America is pleased to announce that its recently acquired subsidiary, Giant Resource Recovery (GRR!), will rebrand to Heidelberg Materials Giant […]

Essy Mozaffari, PharmD, MPH, MBA Joins eMAX Health as Head of Real-World Evidence GlobeNewswire June 02, 2025 DELRAY BEACH, Fla., June 02, 2025 (GLOBE NEWSWIRE) — eMAX Health is pleased to announce the appointment of Essy Mozaffari, PharmD, MPH, MBA as Senior Vice President and Head of Real-World Evidence. Dr. Mozaffari brings over 25 years

WSP acquires specialist healthcare and life sciences consulting firm Lexica GlobeNewswire June 02, 2025 MONTREAL, June 02, 2025 (GLOBE NEWSWIRE) — WSP Global Inc. (TSX: WSP) (“WSP” or the “Corporation”), one of the world's leading professional services firms, announces the acquisition of Lexica, a UK-based consulting firm specializing in healthcare and life sciences. Lexica adds

Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology Patent Strengthens AquaRefining(TM) IP Portfolio and Supports Licensing and Joint Venture Strategy for Global Expansion GlobeNewswire June 02, 2025 RENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that

Solesence Expands Debt Facilities to Fuel Growth Initiatives GlobeNewswire June 02, 2025 ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) — Solesence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased

Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 GlobeNewswire June 02, 2025 Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Erasca,

Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL(R) (bempedoic acid) Prior to April 19, 2040 GlobeNewswire June 02, 2025 ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates

Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl GlobeNewswire June 02, 2025 ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand

Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting GlobeNewswire June 02, 2025 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic payloads,

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab New trial arm to evaluate safety, dosing and preliminary anti-tumor activity of the combination therapy in advanced solid tumors GlobeNewswire June 02, 2025 NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage